<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03087474</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-496</org_study_id>
    <nct_id>NCT03087474</nct_id>
  </id_info>
  <brief_title>Treatment of Venous Thromboembolism in Real-Life Patients</brief_title>
  <official_title>Treatment of Venous Thromboembolism in Real-Life Patients: A Nationwide, Population-Based Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a population of patients with venous thromboembolism and treated with oral anticoagulants
      (OAC) in routine clinical practice in Denmark this study will describe patients treated with
      each OAC
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 4, 2015</start_date>
  <completion_date type="Anticipated">May 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hospitalization rate in VKA patients for VTE</measure>
    <time_frame>Approximately 180 months</time_frame>
    <description>Hospitalization rate for first-time Venous thromboembolism (VTE) in Vitamin K antagonist (VKA) patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VTE hospitalization rate in VKA patients by sex</measure>
    <time_frame>Approximately 180 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>VTE hospitalization rate in VKA patients by age</measure>
    <time_frame>Approximately 180 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospitalization rate in NOAC patients for VTE</measure>
    <time_frame>Approximately 180 months</time_frame>
    <description>Hospitalization rate for first-time venous thromboembolism in nonvitamin K antagonist oral anticoagulants (NOAC) patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VTE hospitalization rate in NOAC patients by sex</measure>
    <time_frame>Approximately 180 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>VTE hospitalization rate in NOAC patients by age</measure>
    <time_frame>Approximately 180 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Treatment in NOAC patients</measure>
    <time_frame>Approximately 180 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of treatment in VKA patients</measure>
    <time_frame>Approximately 180 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">89383</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>VKA patients</arm_group_label>
    <description>Vitamin K antagonist (VKA) patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NOAC patients</arm_group_label>
    <description>nonvitamin K antagonist oral anticoagulants (NOAC) patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-Interventional</intervention_name>
    <description>Non-Interventional</description>
    <arm_group_label>VKA patients</arm_group_label>
    <arm_group_label>NOAC patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The Danish National Patient Registry (DNPR), covering all Danish hospitals, will be used to
        identify first-time and recurrent VTE cases diagnosed from 01-Jan-2006 through 31-Dec-2015.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All patients â‰¥ 18 years diagnosed with incident VTE at Danish public hospitals from
             2006 through 2015

          2. First-time (index) VTE will be defined as an in- or out-patient diagnosis of DVT or PE
             among patients redeeming a prescription for anticoagulant drugs within 30 days after
             index date

        Exclusion Criteria:

        1. In the analyses on type and duration of anticoagulant use, Patients with cancer will be
        excluded as they typically receive low molecular heparin directly from the hospital and
        their use of anticoagulants can therefore not be captured by redeemed prescriptions at
        pharmacies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2017</study_first_submitted>
  <study_first_submitted_qc>March 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2017</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

